| REV7-p53 interaction inhibits ATM-mediated DNA damage signaling. | REV7-p53 interaction inhibits ATM-mediated DNA damage signaling.
Biller M, Kabir S, Boado C, Nipper S, Saffa A, Tal A, Allen S, Sasanuma H, Dréau D, Vaziri C, Tomida J., | 07/15/2024 |
| AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2. | AURKB promotes bladder cancer progression by deregulating the p53 DNA damage response pathway via MAD2L2.
Li L, Jiang P, Hu W, Zou F, Li M, Rao T, Ruan Y, Yu W, Ning J, Cheng F., Free PMC Article | 03/27/2024 |
| MAD2L2, a key regulator in ovarian cancer and promoting tumor progression. | MAD2L2, a key regulator in ovarian cancer and promoting tumor progression.
Xu K, Zheng X, Shi H, Ou J, Ding H., Free PMC Article | 01/8/2024 |
| The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma. | The promoting effect and mechanism of MAD2L2 on stemness maintenance and malignant progression in glioma.
Liu Z, Wang S, Yu K, Chen K, Zhao L, Zhang J, Dai K, Zhao P., Free PMC Article | 12/1/2023 |
| Identification of the promoter region regulating the transcription of the REV7 gene. | Identification of the promoter region regulating the transcription of the REV7 gene.
Shimada Y, Kato T, Sakurai Y, Watanabe H, Nonaka M, Nanaura N, Ichinoe M, Murakumo Y. | 05/10/2023 |
| Bridging Gaps in HDR Improvement: The Role of MAD2L2, SCAI, and SCR7. | Bridging Gaps in HDR Improvement: The Role of MAD2L2, SCAI, and SCR7.
Anuchina AA, Zaynitdinova MI, Demchenko AG, Evtushenko NA, Lavrov AV, Smirnikhina SA., Free PMC Article | 04/17/2023 |
| Evolution of Rev7 interactions in eukaryotic TLS DNA polymerase Polzeta. | Evolution of Rev7 interactions in eukaryotic TLS DNA polymerase Polζ.
McPherson KS, Rizzo AA, Erlandsen H, Chatterjee N, Walker GC, Korzhnev DM., Free PMC Article | 03/8/2023 |
| CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair. | CHAMP1 binds to REV7/FANCV and promotes homologous recombination repair.
Li F, Sarangi P, Iyer DR, Feng H, Moreau L, Nguyen H, Clairmont C, D'Andrea AD., Free PMC Article | 09/24/2022 |
| Oxaliplatin promotes siMAD2L2induced apoptosis in colon cancer cells. | Oxaliplatin promotes siMAD2L2‑induced apoptosis in colon cancer cells.
Ma L, Li X, Zhao X, Sun H, Kong F, Li Y, Sui Y, Xu F., Free PMC Article | 12/18/2021 |
| Inhibition of MAD2B alleviates venous neointimal formation by suppressing VSMCs proliferation and migration. | Inhibition of MAD2B alleviates venous neointimal formation by suppressing VSMCs proliferation and migration.
Song AN, Yin XJ, Gao P, Tang H, Meng XF, Zhang C. | 11/22/2021 |
| MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair. | MAD2L2 dimerization and TRIP13 control shieldin activity in DNA repair.
de Krijger I, Föhr B, Pérez SH, Vincendeau E, Serrat J, Thouin AM, Susvirkar V, Lescale C, Paniagua I, Hoekman L, Kaur S, Altelaar M, Deriano L, Faesen AC, Jacobs JJL., Free PMC Article | 10/16/2021 |
| CDH1 binds MAD2L2 in a Rev1-like pattern. | CDH1 binds MAD2L2 in a Rev1-like pattern.
Pernicone N, Grinshpon S, Listovsky T. | 03/20/2021 |
| Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer. | Rev7 loss alters cisplatin response and increases drug efficacy in chemotherapy-resistant lung cancer.
Vassel FM, Bian K, Walker GC, Hemann MT., Free PMC Article | 01/16/2021 |
| Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors. | Inactivation of REV7 enhances chemosensitivity and overcomes acquired chemoresistance in testicular germ cell tumors.
Sakurai Y, Ichinoe M, Yoshida K, Nakazato Y, Saito S, Satoh M, Nakada N, Sanoyama I, Umezawa A, Numata Y, Shi-Xu J, Ichihara M, Takahashi M, Murakumo Y. | 01/16/2021 |
| p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase. | p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase.
Sarangi P, Clairmont CS, Galli LD, Moreau LA, D'Andrea AD., Free PMC Article | 12/19/2020 |
| MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis. | MDA-MB-157 Cell Line Presents High Levels of MAD2L2 and Dysregulated Mitosis.
Pernicone N, Peretz L, Grinshpon S, Listovsky T. | 10/10/2020 |
| Structural basis for shieldin complex subunit 3-mediated recruitment of the checkpoint protein REV7 during DNA double-strand break repair. | Structural basis for shieldin complex subunit 3-mediated recruitment of the checkpoint protein REV7 during DNA double-strand break repair.
Dai Y, Zhang F, Wang L, Shan S, Gong Z, Zhou Z., Free PMC Article | 09/12/2020 |
| REV7 preferentially binds GTP-bound RAN, implying that a GTP/GDP-bound transition of RAN may serve as the molecular switch that controls REV7's activity. | REV7 has a dynamic adaptor region to accommodate small GTPase RAN/Shigella IpaB ligands, and its activity is regulated by the RanGTP/GDP switch.
Wang X, Pernicone N, Pertz L, Hua D, Zhang T, Listovsky T, Xie W., Free PMC Article | 06/6/2020 |
| Our study showed that MAD2B expression significantly increased in lung cancer, especially in the metastatic tissues.. these findings indicate an oncogenic role of MAD2B in lung cancer, and slug might be involved in the process. | Mitotic Arrest-Deficient Protein 2B Overexpressed in Lung Cancer Promotes Proliferation, EMT, and Metastasis.
Zhang H, He X, Yu W, Yue B, Yu Z, Qin Y., Free PMC Article | 01/11/2020 |
| these results establish SHLD2 as a novel effector of REV7 in controlling the decision-making process during DSB repair. | SHLD2/FAM35A co-operates with REV7 to coordinate DNA double-strand break repair pathway choice.
Findlay S, Heath J, Luo VM, Malina A, Morin T, Coulombe Y, Djerir B, Li Z, Samiei A, Simo-Cheyou E, Karam M, Bagci H, Rahat D, Grapton D, Lavoie EG, Dove C, Khaled H, Kuasne H, Mann KK, Klein KO, Greenwood CM, Tabach Y, Park M, Côté JF, Masson JY, Maréchal A, Orthwein A., Free PMC Article | 10/5/2019 |
| the differential H4K20 methylation status between pre-replicative and post-replicative DNA represents an intrinsic mechanism that locally ensures appropriate recruitment of the 53BP1-RIF1-MAD2L2 complex at DNA double strand breaks. | H4K20me2 distinguishes pre-replicative from post-replicative chromatin to appropriately direct DNA repair pathway choice by 53BP1-RIF1-MAD2L2.
Simonetta M, de Krijger I, Serrat J, Moatti N, Fortunato D, Hoekman L, Bleijerveld OB, Altelaar AFM, Jacobs JJL., Free PMC Article | 09/7/2019 |
| Mechanistically, MAD2B physically interacted with TCF4 to repress TCF4 transcriptional activity via beta-catenin mediation, leading to reduced beta-catenin/TCF4-dependent transactivation and Wnt signaling activity. These results demonstrate, for the first time, that MAD2B plays a negative role in TCF4-induced dermal papilla cell growth and proliferation. | MAD2B acts as a negative regulatory partner of TCF4 on proliferation in human dermal papilla cells.
Yu N, Song Z, Zhang K, Yang X., Free PMC Article | 07/6/2019 |
| REV7-PRDX2 complex also assembled onto DNA double-strand breaks. | REV7 confers radioresistance of esophagus squamous cell carcinoma by recruiting PRDX2.
Gu C, Luo J, Lu X, Tang Y, Ma Y, Yun Y, Cao J, Cao J, Huang Z, Zhou X, Zhang S., Free PMC Article | 03/9/2019 |
| found FAM35A, a previously unstudied protein with an unstructured N-terminal region and a C-terminal region harboring three OB-fold domains similar to single-stranded DNA-binding protein RPA, as novel interactor of REV7/RIF1/53BP1. | FAM35A associates with REV7 and modulates DNA damage responses of normal and BRCA1-defective cells.
Tomida J, Takata KI, Bhetawal S, Person MD, Chao HP, Tang DG, Wood RD., Free PMC Article | 02/23/2019 |
| Increased MAD2L2 expression in colorectal cancer cells activated p38, which was required for the phosphorylation of NCOA3 that led to its ubiquitination and degradation by the proteasome. | MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.
Li Y, Li L, Chen M, Yu X, Gu Z, Qiu H, Qin G, Long Q, Fu X, Liu T, Li W, Huang W, Shi D, Kang T, Luo M, Wu X, Deng W., Free PMC Article | 02/23/2019 |